CJC-1295 (No DAC) Buyer's Guide 2026: Specs, Sourcing, and Red Flags

At a Glance: Sourcing Research-Grade CJC-1295 (No DAC)

CJC-1295 (No DAC), also classified in scientific literature as Modified GRF (1-29), is a synthetic 29-amino acid tetrasubstituted peptide functioning as a growth hormone-releasing hormone (GHRH) analog. Research models evaluate this compound for its ability to selectively bind pituitary GHRH receptors, inducing pulsatile growth hormone (GH) secretion and elevating circulating insulin-like growth factor 1 (IGF-1) to facilitate downstream tissue repair and cellular signaling studies.

Unlike formulations bound to Drug Affinity Complex (DAC), the non-DAC variant exhibits a distinct, rapid pharmacokinetic profile without prolonged half-life extension. This permits investigators precise temporal control over GH release kinetics during controlled in vitro assays and animal models.

Sourcing high-integrity cjc 1295 reagents requires strict validation of identity, sequence sequence homogeneity, counterion removal, and sterility. Principal investigators must look beyond basic purity percentages and insist on comprehensive HPLC, mass spectrometry, and endotoxin quantification before introducing material into active research protocols. Researchers ready to secure validated lots can order 5 mg vials of CJC-1295 (No DAC) directly from PX1 Research.

What Is CJC-1295 (No DAC)? Chemical Structure and Molecular Profile

To properly utilize CJC-1295 (No DAC) in laboratory experiments, investigators must understand its structural evolution from endogenous GHRH. Endogenous growth hormone-releasing hormone consists of a 44-amino acid structure, though the N-terminal 1-29 fragment contains full biological activity. However, wild-type GRF (1-29) suffers rapid enzymatic degradation in plasma, primarily via dipeptidyl peptidase-IV (DPP-IV) cleavage at the Tyr1-Ala2 position.

Modified GRF (1-29), commonly termed cjc no dac, incorporates four strategic amino acid substitutions to resist rapid enzymatic hydrolysis: D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27. These alterations yield a molecular formula of C152H252N44O42 and a exact molecular weight of approximately 3367.2 g/mol. This structural modification enhances plasma stability while preserving physiological receptor affinity.

In cell culture and animal models, this tetrasubstituted analog binds to the GHRH receptor on pituitary somatotropes. Activation triggers cyclic adenosine monophosphate (cAMP) signaling pathways, resulting in exocytosis of stored growth hormone. Because it lacks the Drug Affinity Complex moiety—a lysine modification that irreversibly binds serum albumin—CJC-1295 (No DAC) clears rapidly, allowing researchers to simulate discrete, physiological GH pulses rather than sustained basal elevations.

CJC-1295 (No DAC) vs. CJC-1295 (With DAC): Key Differences in Preclinical Research

A frequent point of confusion in peptide procurement is the distinction between CJC-1295 with DAC and CJC-1295 without DAC. Selecting the correct analog is critical for experimental reproducibility, as their pharmacokinetic and pharmacodynamic profiles differ substantially in preclinical models.

CJC-1295 with DAC includes a maleimidopropionic acid linker covalently attached to the C-terminus. This linker forms a stable thioether bond with circulating albumin upon administration in vivo, extending the elimination half-life from approximately 30 minutes to several days. This leads to continuous, non-pulsatile secretion of growth hormone and chronically elevated IGF-1 levels in study subjects.

In contrast, CJC-1295 (No DAC) exhibits a half-life of roughly 30 minutes in animal models. It delivers a transient, sharp pulse of growth hormone secretion that returns to baseline within hours. For investigators modeling physiological pituitary behavior, circadian GH rhythms, or acute tissue regeneration signaling, the non-DAC variant is the standard reagent. You can review experimental specifications for both variants across our complete catalog of research peptides or inspect the alternative CJC-1295 with DAC product details.

Why Is CJC-1295 (No DAC) Frequently Studied with Ipamorelin?

In endocrine and cell biology literature, researchers frequently examine dual-stimulus growth hormone secretagogue protocols. The combination often designated in literature as cjc ipamorelin pairs a GHRH analog with a selective Growth Hormone Secretagogue Receptor (GHSR-1a) agonist.

GHRH analogs like CJC-1295 (No DAC) activate the GHRH pathway, increasing cAMP accumulation inside somatotropes. Concurrently, ghrelin receptor agonists like Ipamorelin trigger the phosphoinositide pathway, increasing intracellular calcium concentrations. When exposed to both signals simultaneously, pituitary cells demonstrate a synergistic amplification of GH release that significantly exceeds the additive effect of either agent administered individually.

Furthermore, because Ipamorelin is highly selective and does not stimulate cortisol, prolactin, or aldosterone secretion, pairing it with CJC-1295 (No DAC) allows scientists to isolate GH/IGF-1 axis dynamics without confounding secondary hormonal spikes. Research teams exploring dual-pathway secretagogue mechanisms can source research-grade Ipamorelin 5 mg alongside their GHRH reagents to maintain baseline analytical consistency across control and experimental cohorts.

Essential Quality Standards for Sourcing CJC-1295 (No DAC) in 2026

As analytical instrumentation advances, vendor verification standards in 2026 require far more than high-performance liquid chromatography (HPLC) peak integration. Evaluating CJC-1295 (No DAC) for laboratory use requires strict verification across four primary chemical benchmarks:

1. Chromatographic Purity (HPLC): The main peak area must represent ≥99.0% of total integrated UV absorbance at 214 nm and 280 nm. Impurities, including truncated sequences or oxidation products, must remain strictly below 1.0% cumulative area.

2. Mass Spectrometry (MS) Sequence Identity: Electrospray ionization mass spectrometry (ESI-MS) or MALDI-TOF must yield a primary monoisotopic mass matching the theoretical target of 3367.2 Da (±0.5 Da), verifying correct amino acid assembly without missing residues.

3. Residual Counterion and TFA Content: Solid-phase peptide synthesis (SPPS) utilizes trifluoroacetic acid (TFA) for cleavage. Excessive residual TFA salts introduce cellular toxicity in cell culture assays. High-grade reagents must undergo counterion exchange to minimize TFA content to negligible levels.

4. Bacterial Endotoxin Levels: For in vivo rodent studies or sensitive cell lines, endotoxin contamination can trigger inflammatory cascades, invalidating metabolic and gene expression assays. Reagents must pass Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels measure under <0.01 EU/mg.

Sourcing Rubric: Evaluating Vendor Criteria for Research Peptides

When purchasing laboratory reagents, procurement specialists should evaluate vendors using a standardized criteria framework rather than relying on marketing claims. The following evaluation matrix outlines the minimum standards required for repeatable, publication-grade research:

Red Flags: How to Identify Low-Quality Peptide Suppliers

The online reagent market contains numerous suppliers who compromise analytical rigor to reduce costs. Identifying these commercial red flags protects research budgets and ensures dataset integrity.

Red Flag 1: Static or Template Certificates of Analysis (COAs). Many vendors display a single, non-downloadable COA on their product page that remains unchanged for years. A legitimate supplier generates a unique, lot-specific COA for every production run, performed by an independent, accredited US analytical laboratory.

Red Flag 2: Ambiguous Purity Claims Without Raw Analytical Data. Statements claiming '99% Pure' without attached HPLC chromatograms showing integration tables and base-line separation are unverifiable. High-purity claims must be backed by full-spectrum UV chromatographs.

Red Flag 3: Lack of Endotoxin Testing Data. Suppliers offering peptides for biological research without conducting LAL gel-clot or chromogenic endotoxin testing expose research models to lipopolysaccharide (LPS) contamination. LPS triggers massive immune activation in cell cultures and laboratory animals.

Red Flag 4: Unregulated Compound Blends or Off-Label Claims. Reputable supply houses strictly sell individual, purified chemical entities labeled for laboratory research use only. Vendors making therapeutic claims, providing human dosing charts, or selling non-standard unquantified mixtures operate outside scientific quality standards. Investigators requiring verified GHRH standards should reference our guide on GHRH analog comparative research or view Sermorelin acetate standards for alternative sequence comparisons.

Vial Specifications, Reconstitution, and In Vitro Handling

PX1 Research supplies CJC-1295 (No DAC) in vacuum-sealed, lyophilized glass vials designed to preserve structural stability during transport and storage. Proper handling protocols are critical to maintaining peptide integrity upon arrival at the research facility.

Reconstitution Protocols: Lyophilized cakes should be reconstituted using sterile bacteriostatic water (0.9% benzyl alcohol) or sterile isotonic saline, depending on the requirements of the downstream biological assay. Solvent should be introduced gently along the glass vial wall rather than sprayed directly onto the peptide cake to prevent shear stress and aggregation.

Solubility Characteristics: CJC-1295 (No DAC) exhibits high solubility in aqueous buffers at neutral pH. Swirling the vial gently until the solution is clear ensures complete solvation. Vortexing or vigorous shaking must be strictly avoided, as mechanical agitation can disrupt secondary peptide folding.

Concentration Calculations: For controlled micro-dosing in automated pipetting platforms or animal injection systems, reconstituting a standard 5 mg vial with 2.0 mL of diluent yields a working concentration of 2.5 mg/mL (2500 mcg/mL). Investigators requiring detailed molecular calculations can access our PX1 peer-reviewed research database for solvent compatibility tables.

Storage Conditions and Peptide Stability Protocols

Maintaining chemical stability requires strict adherence to temperature and environmental controls before and after reconstitution.

Lyophilized Storage: Prior to reconstitution, lyophilized CJC-1295 (No DAC) powder remains stable at -20°C for up to 24 months. Desiccant containers should be utilized to protect vials from atmospheric moisture ingress during long-term freezer storage.

Reconstituted Storage: Once solvated, the peptide solution should be stored at 2°C to 8°C (36°F to 46°F) and shielded from direct light exposure. Liquid aliquots remain stable under refrigeration for up to 30 days when prepared with bacteriostatic solvents. Repeated freeze-thaw cycles must be avoided, as ice crystal formation degrades the peptide backbone; if long-term storage of liquid stock is required, solution aliquots should be frozen immediately at -80°C and thawed only once prior to use.

For trials requiring multi-target tissue repair assays, researchers often cross-reference GHRH data with cytoprotective peptides like BPC-157 lyophilized powder to evaluate cellular migration and extracellular matrix expression.

Ordering CJC-1295 (No DAC) from PX1 Research

When purchasing CJC-1295 (No DAC) for preclinical projects, PX1 Research provides the analytical transparency, speed, and regulatory compliance necessary for rigorous scientific work. Every vial shipped from our facilities meets exact chemical purity benchmarks verified by independent laboratory testing.

What Ships: Each order includes vacuum-sealed, tamper-evident 5 mg vials of lyophilized CJC-1295 (No DAC), packaged in climate-controlled protective casing. Lot numbers printed on each vial correspond directly to downloadable analytical reports on our portal.

Shipping Cutoffs and Logistics: Orders placed before 3:00 PM EST (Monday–Friday) ship the same day from our primary logistics centers in California and Arizona. Expedited, fully tracked domestic shipping ensures your reagents arrive without prolonged ambient temperature exposure.

Analytical Assurance: Every lot undergoes mandatory HPLC, ESI-MS, and endotoxin assay testing. Researchers can inspect real-time analytical reports prior to purchase on the PX1 CJC-1295 (No DAC) product page. For laboratory teams managing large-scale screening projects, PX1 also offers structured options for bulk research peptide sourcing.

Ready to advance your GH axis and cellular signaling protocols with fully verified reagents? Visit the official product page now to review live COAs and order 5 mg vials of CJC-1295 (No DAC).